Compounds to Preserve Memory for Alzheimer's Disease

NeuroLucent CSO, Beth Stutzmann, Ph.D, has identified the underlying neuronal mechanisms causing the synaptic dysfunction leading to Alzheimer’s disease (AD). With a focus on developing compounds that restore healthy neuronal signaling, NeuroLucent has an exclusive license to the intellectual property, including patents, of Rosalind Franklin University of Medicine and Science (“RFUMS”) and has begun the commercialization process. Unlike existing treatments that only temporarily slow the progression of memory loss, our compounds stop the early Ca2+ dysregulation at the cellular level, keeping synaptic health and memory function intact.

• 1 in 8 people >65 years old has AD
• This health crisis will escalate, imminently
• $226B spent annually and >$14B Market by 2020​
• NeuroLucent will halt the progression of AD with novel compounds that prevent the early disease mechanisms

Four major areas of interest by researchers for Alzheimer's Disease, and yet:

• Amyloid plaques – 10+ failed phase 3 clinical trials
• Neurofibrillary tangles – Association with memory loss is unclear, late stage feature
• Cholinergic cell loss – Over $4B is spent annually on cholinesterase inhibitors. Yet they do not treat the underlying disease, preserve synaptic function, or alter the slope of cognitive decline
• Synaptic loss – The only feature of AD that correlates with cognitive impairment, which our science addresses

​​